Literature DB >> 11074473

Serological pattern "anti-HBc alone": report on a workshop.

P Grob1, W Jilg, H Bornhak, G Gerken, W Gerlich, S Günther, G Hess, H Hüdig, A Kitchen, H Margolis, G Michel, C Trepo, H Will, A Zanetti, I Mushahwar.   

Abstract

In areas with low hepatitis B virus (HBV) endemicity such as most parts of Europe and the United States "anti-HBc alone" is found in 10-20% of all individuals with HBV markers, i.e., 1-4% of the population. In about 10% of these individuals HBV DNA is detected by PCR, the proportions varying greatly depending on the population studied, being highest in individuals coinfected with hepatitis C virus (HCV) (above 35%) and HIV (above 85%). A small proportion of individuals with "anti-HBc alone" are in the window phase of an HBV infection or in a stage of late HBV immunity. For the large proportion of these individuals this is not the case and they are thought to have an unresolved HBV-infection or a chronic infection in a late or "low grade" productive state. Currently, limited studies have been performed concerning the clinical aspects of individuals with "anti-HBc alone" and suspected chronic HBV infection. The majority of these individuals seem to be healthy. Some chronic carriers with "anti-HBc alone," however, do present signs of chronic hepatitis. Individuals with "anti-HBc alone" are potentially infectious. This is exemplified by a few case reports of HBV transmission to sexual contacts, perinatal transmission between mother and newborns and in blood recipients. Recommendations are given in relation to both the diagnostic and therapeutic procedures in the individuals with "anti-HBc alone" and in the blood banking and transplantation services. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11074473     DOI: 10.1002/1096-9071(200012)62:4<450::aid-jmv9>3.0.co;2-y

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  54 in total

1.  Serological pattern "anti-HBc alone": characterization of 552 individuals and clinical significance.

Authors:  Antje Knöll; Arndt Hartmann; Harald Hamoshi; Karin Weislmaier; Wolfgang Jilg
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

2.  Isolated Hepatitis B Core Antibody Status Is Not Associated With Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection.

Authors:  Audrey L French; Anna Hotton; Mary Young; Marek Nowicki; Michael Augenbraun; Kathryn Anastos; Eric Seaberg; William Rosenberg; Marion G Peters
Journal:  J Acquir Immune Defic Syndr       Date:  2016-07-01       Impact factor: 3.731

3.  Novel double-antigen sandwich immunoassay for human hepatitis B core antibody.

Authors:  An Li; Quan Yuan; Zhiyin Huang; Jian Fan; Ruyi Guo; Bin Lou; Qin Zheng; Shengxiang Ge; Yixin Chen; Zhijun Su; Anthony E T Yeo; Yu Chen; Jun Zhang; Ningshao Xia
Journal:  Clin Vaccine Immunol       Date:  2010-01-27

4.  [4. Austrian consensus-statement for diagnosis and therapy of hepatitis B 2009].

Authors:  Markus Peck-Radosavljevic; Johann Deutsch; Peter Ferenci; Ivo Graziadei; Harald Hofer; Heidemarie Holzmann; Wolf-Dietrich Huber; Herman Laferl; Andreas Maieron; Rudolf Stauber; Wolfgang Vogel
Journal:  Wien Klin Wochenschr       Date:  2010-05-04       Impact factor: 1.704

5.  The Role of anti-HBc IgM in Screening of Blood Donors.

Authors:  H Kumar; P K Gupta; M Jaiprakash
Journal:  Med J Armed Forces India       Date:  2011-07-21

6.  Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only serological marker.

Authors:  A J Chamorro; J L Casado; D Bellido; S Moreno
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-07       Impact factor: 3.267

7.  Clinical significance of "anti-HBc alone" in human immunodeficiency virus-positive patients.

Authors:  Ma Teresa Pérez-Rodríguez; Bernardo Sopeña; Manuel Crespo; Alberto Rivera; Teresa González del Blanco; Antonio Ocampo; César Martínez-Vázquez
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

8.  Prevalence, risk factors, and impact of isolated antibody to hepatitis B core antigen and occult hepatitis B virus infection in HIV-1-infected pregnant women.

Authors:  Woottichai Khamduang; Nicole Ngo-Giang-Huong; Catherine Gaudy-Graffin; Gonzague Jourdain; Weerapong Suwankornsakul; Tapnarong Jarupanich; Veeradate Chalermpolprapa; Sirisak Nanta; Noossara Puarattana-Aroonkorn; Sakchai Tonmat; Marc Lallemant; Alain Goudeau; Wasna Sirirungsi
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

9.  Molecular characteristics of occult hepatitis B virus from blood donors in southeast China.

Authors:  Quan Yuan; Shan-Hai Ou; Chang-Rong Chen; Sheng-Xiang Ge; Bin Pei; Qing-Rui Chen; Qiang Yan; Yong-Cai Lin; Hong-Ying Ni; Cheng-Hao Huang; Anthony E T Yeo; James W K Shih; Jun Zhang; Ning-Shao Xia
Journal:  J Clin Microbiol       Date:  2009-11-25       Impact factor: 5.948

10.  Clinical significance of antibody to hepatitis B core antigen in multitransfused hemodialysis patients.

Authors:  Doaa M Elghannam; Rabab M Aly; Enas F Goda; Ehab E Eltoraby; Raghda E Farag
Journal:  Asian J Transfus Sci       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.